Brigatinib received accelerated approval from FDA

On April 28, 2017, the U.S. Food and Drug Administration granted accelerated approval to brigatinib for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Read more: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555841.htm